Audible. Only £0.99 a month for the first 3 months + £10 Audible voucher. Pay £0.99 for the first 3 months, and £7.99/month thereafter. Renews automatically. Start my membership.

Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study
Nov 19 2024
Length: 3 mins
Podcast

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Unfollow podcast failed

Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study

Listen for free

View show details

Summary
Author: Strober J, et al.
Overview Provided by Nicolas Silvestri, MD

Show More Show Less

Show More Show Less

What listeners say about Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews

No Reviews are Available

Report a review on Amazon